Advanced search for publications
Enter your keywords
NHS Medicines Optimisation Opportunities Dashboard 2023-24
At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver […]
Drugs used in Diabetes
This report looks at prescribing trends in primary care for Drugs used in Diabetes at SICBL and ICB level with particular focus on insulins, anti-diabetic drugs and diagnostic & monitoring devices. Prescribing data is weighted with QOF registers, and also uses HES data to measure prescribing outcomes. If you have any queries about the content […]
Defining the type-2 diabetic population: a first step to understanding the impact of pathway choices
Strategic Insight reports are designed to support strategic objectives and planning by Integrated Care System leaders. The aim of this report is to determine current prescribing patterns and prescribing costs of antidiabetic treatments across the ICBs in the North of England with a particular emphasis on SGLT-2 inhibitors and GLP-1 mimetics. This will enable organisations […]
Budget impact of metformin 1g immediate release tablet prescribing
The purpose of this bulletin is to highlight the rapid increase in price of metformin 1g tablets over the last year, and to raise awareness of the difference in price of metformin 1g immediate release (IR) tablets compared with 500mg IR tablets. It considers the potential budget impact to primary care of prescribing metformin 1g […]
Formulary assessment – Glucagon (Ogluo)
Comparison of DPP-4 inhibitors (Gliptins)
There are currently five dipeptidyl peptidase-4 (DPP-4) inhibitors (or gliptins) available in the UK for the management of type 2 diabetes mellitus. There are a number of differences between the DPP-4 inhibitors in terms of licensing, interactions, renal impairment dose adjustment, hepatic impairment dose adjustment, and cost. This comparison table allows prescribers and other healthcare […]
Formulary assessment – estradiol/progesterone (Bijuve) for HRT
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies. The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The […]
Estradiol / progesterone (Bijuve®) for hormone replacement therapy in postmenopausal women
Download the full review below to read more. A Formulary Assessment Tool is also available on this topic. Formulary Assessment Tools are pre-populated templates with space for local adaptation, to reduce duplication and support decision-making.
Formulary assessment – estradiol spray (Lenzetto)
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies. The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The […]
Formulary assessment – testosterone 2% gel (Tostran) in post-menopausal women
Formulary assessment tools are templates to support local decision making. They list NICE guidance, MHRA safety advice, and other relevant high quality advice and guidelines relevant to making decisions for local formularies. The templates are pre-populated with useful information to reduce duplication of effort, with space for the addition of local information as appropriate. The […]